Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level
KVA12123 Monotherapy Demonstrated Dose Proportional Induction of Pro-inflammatory Biomarkers Required for Strong Anti-tumor Activity
Related news for (KA)
- Fiber, Helium, and AI Heat Up the Final Stretch — Watch These Stocks into the Close
- Scarcity, AI, and Steel: Microcaps Fuel the Morning Narrative
- Don’t Miss Out: MoBot’s Latest Stock Updates 10/17/25 07:00 AM
- MoBot alert highlights: NASDAQ: AKAN, NASDAQ: KMRK, NYSE: GWH, NASDAQ: CREV, NASDAQ: SGBX (10/17/25 06:00 AM)
- MoBot alert highlights: NASDAQ: AKAN, NASDAQ: CREV, NASDAQ: SGBX, NASDAQ: RGTZ, NASDAQ: ARTV (10/17/25 05:00 AM)